[1] Vanwolleghem T, Libbrecht L, Hansen BE, et al.Factors determining successful engraftment of hepatocytes and susceptibility to hepatitis B and C virus infection in uPA-SCID mice[J]. J Hepatol, 2010, 53(3):468-476. [2] Houghton M.The long and winding road leading to the identification of the hepatitis C virus[J]. J Hepatol, 2009, 51(5):939-948. [3] Muchmore E, Popper H, Peterson DA, et al.Non-A, non-B hepatitis-related hepatocellular carcinoma in a chimpanzee[J]. J Med Primatol, 1988, 17(5):235-246. [4] Olsen DB, Davies ME, Handt L, et al.Sustained viral response in a hepatitis C virus-infected chimpanzee via a combination of direct acting antiviral agents[J]. Antimicrob Agents Chemother, 2011, 55(2):937-939. [5] Tomoguri T, Katayama K, Tanaka J, et al.Interferon alone or combined with ribavirin for acute prolonged infection with hepatitis C virus in chimpanzees[J]. Intervirology, 2011, 54(4):229-232. [6] Thimme R, Bukh J, Spangenberg HC, et al.Viral and immunological determinants of hepatitis C virus clearance, persistence, and disease[J]. Proc Natl Acad Sci USA, 2002, 99(24):15661-15668. [7] Shoukry NH, Sidney J, Sette A, et al.Conserved hierarchy of helper T cell response in a chimpanzee during primary and secondary hepatitis C virus infections[J]. J Immunol, 2004, 172(1):483-492. [8] Barth H, Rybczynska J, Patient R, et al.Both innate and adaptive immunity mediate protective immunity against hepatitis C virus infection in chimpanzees[J]. Hepatol, 2011, 54(4):1135-1148. [9] Kolykhalov AA, Agapov EV, Blight KJ.et al.Transmission of hepatitis C by intrahepatic inoculation with transcribed RNA[J]. Sci,1997, 277:570-574. [10] Grakoui A, Shoukry NH, Woollard DJ, et al.HCV persistence and immune evasion in the absence of memory T cell help[J]. Sci , 2003, 302:659-662. [11] Houghton M.Prospects for prophylactic and therapeutic vaccines against the hepatitis C viruses[J]. Immunol. 2011, 239:99-108. [12] Lanford RE, Hildebrandt-Eriksen ES, Petri A, et al.Therapeutic silencing of microRNA-122 in primates with chronic hepatitis C virus infection[J]. Sci, 2010, 327:198-201. [13] Mercer DF, Schiller DE, Elliott JF, et al.Hepatitis C virus replication in mice with chimeric human livers[J]. Nat Med, 2001, 7(8):927-933. [14] Meuleman P, Libbrecht L, De Vos R, et al.Morphological and biochemical characterization of a human liver in a uPA-SCID mouse chimera[J]. Hepatol, 2005, 41(4):847-856. [15] Steenbergen RH, Joyce MA, Lund G, et al.Lipoprotein profiles in SCID/uPA mice transplanted with human hepatocytes become human-like and correlate with HCV infection success[J]. Am J Physiol Gastrointest Liver Physiol, 2010, 299(4):G844-G854. [16] Kamiya N, Iwao E, Hiraga N, et al.Practical evaluation of a mouse with chimeric human liver model for hepatitis C virus infection using an NS3-4A protease inhibitor[J]. J Gen Virol, 2010, 91(Pt 7):1668-1677. [17] Ouyang EC, Wu CH, Walton C, et al.Transplantation of human hepatocytes into tolerized genetically immunocompetent rats[J]. World J Gastroenterol, 2001, 7(3): 324-330. [18] Wu GY, Konishi M, Walton CM, et al.A novel immunocompetent rat model of HCV infection and hepatitis[J]. Gastroenterol, 2005, 128(5): 1416-1423. [19] Barth H, Robinet E, Liang TJ, et al.Mouse models for the study of HCV infection and virus-host interactions[J]. J Hepatol, 2008, 49(1):134-142. [20] Washburn ML, Bility MT, Zhang L, et al.A humanized mouse model to study hepatitis C virus infection, immune response, and liver disease[J].Gastroenterol, 2011, 140(4):1334-1344. [21] Bukh J, Meuleman P, Tellier R, et al.Challenge pools of hepatitis C virus genotypes 1-6 prototype strains: replication fitness and pathogenicity in chimpanzees and human liver-chimeric mouse models[J]. J Infect Dis, 2010, 201:1381-1389. [22] Naas T, Ghorbani M, Alvarez-Maya I, et al.Characterization of liver histopathology in a transgenic mouse model expressing genotype 1a hepatitis C virus core and envelope proteins 1 and 2[J]. J Gen Virol, 2005, 86(Pt 8): 2185-2196. [23] Koike K, Moriya K, Matsuura Y.Animal models for hepatitis C and related liver disease[J].Hepatol Res, 2010, 40(1):69-82. [24] 闫虎, 路遥, 杜娟, 等. 丙型肝炎病毒NS3/4A丝氨酸蛋白酶瞬时表达小鼠模型的建立[J].生物技术通讯, 2011, 22(4):527-531. [25] Satoh K, Takahashi H, Matsuda C, et al.Natural killer cells target HCV core proteins during the innate immune response in HCV transgenic mice[J]. J Med Virol, 2010, 82(9):1545-1553. [26] Xie ZC, Riezu-Boj JI, Lasarte JJ, et al.Transmission of hepatitis C virus infection to tree shrews[J]. Virol, 1998, 244(2):513-520. [27] Amako Y, Tsukiyama-Kohara K, Katsume A, et al.Pathogenesis of Hepatitis C Virus Infection in Tupaia belangeri[J]. J Virol, 2010, 84(1):303-311. [28] Tong Y, Zhu Y, Xia X, et al.Tupaia CD81, SR-BI, claudin-1, and occludin support hepatitis C virus infection[J]. J Virol, 2011, 85(6):2793-2802. [29] Xu X, Chen H, Cao X, et al.Efficient infection of tree shrew (Tupaia belangeri) with hepatitis C virus grown in cell culture or from patient plasma[J]. J Gen Virol, 2007, 88(Pt9): 2504-2512. |